. Author manuscript; available in PMC: 2020 Jan 1.

Published in final edited form as: Acta Neuropathol. 2018 Oct 31;137(1):71–88. doi: 10.1007/s00401-018-1925-9

Table 1.

Study participant characteristics.

Analysis	Variable	FTLD	Controls	P-Value
Discovery (n = 2,661)	n	62	2,599	NA
	Age at death or last visit (Mean ± SD)	68.6 ± 7.34	85.9 ± 3.55	< 0.001
	Sex (M / F)	35 / 27	1,163 / 1,436	NS
	Age of Onset (n = 32)^*	60.0 ± 7.35	NA	NA
	Disease Duration (n = 32)^*	9.56 ± 3.58	NA	NA
	Pathological Type (Tau / TDP)	24 / 38	NA	NA

Refined (n = 3,635)	n	94	3,541	NA
	Age at death or last visit (Mean ± SD)	67.8 ± 8.39	86.0 ± 3.63	< 0.001
	Sex (M / F)	49 / 45	1,419 / 2,122	< 0.05
	Age of Onset (n = 62)^*	59.2 ± 8.80	NA	NA
	Disease Duration (n = 62)^*	8.98 ± 3.32	NA	NA
	Pathological Type (Tau / TDP / FUS / UPS)	51 / 37 / 5 / 1	NA	NA

Summary demographic and clinical information for participants included in the discovery and refined analyses. The refined analysis includes 54 FTLD cases and 2,085 controls from the discovery analysis, and an additional 40 FTLD cases and 1,456 controls

Age of onset and disease duration was available for the indicated number of participants included in each analysis. M, male; F, female; SD, standard deviation; NA, not applicable; NS, not significant. TDP, TAR DNA-binding protein 43; FUS, Fused in sarcoma; UPS, ubiquitin positive.